ProPhase Total Liab vs Inventory Analysis

PRPH Stock

USD 0.75 0.01 1.35%

ProPhase Labs financial indicator trend analysis is much more than just breaking down ProPhase Labs prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ProPhase Labs is a good investment. Please check the relationship between ProPhase Labs Total Liab and its Inventory accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProPhase Labs. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.

Total Liab vs Inventory

Total Liab vs Inventory Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ProPhase Labs Total Liab account and Inventory. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between ProPhase Labs' Total Liab and Inventory is 0.59. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Inventory in the same time period over historical financial statements of ProPhase Labs, assuming nothing else is changed. The correlation between historical values of ProPhase Labs' Total Liab and Inventory is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of ProPhase Labs are associated (or correlated) with its Inventory. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Inventory has no effect on the direction of Total Liab i.e., ProPhase Labs' Total Liab and Inventory go up and down completely randomly.

Correlation Coefficient

0.59

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Inventory

Most indicators from ProPhase Labs' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ProPhase Labs current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProPhase Labs. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.The ProPhase Labs' current Sales General And Administrative To Revenue is estimated to increase to 0.82, while Selling General Administrative is projected to decrease to under 32.8 M.

	2021	2022	2023	2024 (projected)
Gross Profit	32.8M	70.7M	16.2M	14.0M
Total Revenue	79.0M	122.6M	44.4M	35.5M

Gross Profit Total Revenue

ProPhase Labs fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Other Current Liab	Common Stock Total Equity	Common Stock	Other Assets
Total Assets		0.93	0.87	0.93	0.71	0.33	0.94	0.54	0.95	0.39	0.77	0.97	0.81	0.5	0.86	0.59	-0.12	0.88	0.92	0.85	0.89	0.93	-0.04	-0.29	-0.29	0.71
Total Current Liabilities	0.93		0.7	0.95	0.77	0.01	0.96	0.42	0.95	0.25	0.65	0.93	0.83	0.53	0.88	0.65	-0.3	0.93	0.96	0.91	0.74	0.94	0.09	-0.31	-0.31	0.5
Total Stockholder Equity	0.87	0.7		0.67	0.34	0.55	0.69	0.67	0.7	0.31	0.81	0.86	0.71	0.57	0.56	0.56	0.04	0.73	0.65	0.57	0.99	0.74	-0.1	-0.29	-0.29	0.72
Property Plant And Equipment Net	0.93	0.95	0.67		0.88	0.11	0.99	0.37	0.99	0.44	0.6	0.9	0.73	0.4	0.96	0.55	-0.23	0.85	0.99	0.93	0.7	0.9	-0.06	-0.28	-0.28	0.59
Net Debt	0.71	0.77	0.34	0.88		-0.13	0.87	0.01	0.87	0.44	0.25	0.67	0.49	0.12	0.93	0.32	-0.26	0.64	0.88	0.87	0.37	0.74	-0.07	-0.1	-0.1	0.41
Retained Earnings	0.33	0.01	0.55	0.11	-0.13		0.07	0.41	0.14	0.27	0.4	0.24	0.21	-0.04	0.02	-0.22	0.52	-0.08	0.04	0.03	0.49	0.16	-0.23	0.0	0.0	0.67
Accounts Payable	0.94	0.96	0.69	0.99	0.87	0.07		0.39	0.99	0.39	0.64	0.92	0.77	0.42	0.96	0.57	-0.3	0.89	0.99	0.91	0.73	0.93	0.0	-0.24	-0.23	0.57
Cash	0.54	0.42	0.67	0.37	0.01	0.41	0.39		0.37	0.25	0.92	0.47	0.48	0.39	0.36	0.57	-0.11	0.41	0.41	0.08	0.71	0.38	0.14	-0.26	-0.26	0.31
Non Current Assets Total	0.95	0.95	0.7	0.99	0.87	0.14	0.99	0.37		0.37	0.61	0.92	0.79	0.39	0.95	0.52	-0.24	0.85	0.98	0.94	0.72	0.94	0.03	-0.23	-0.23	0.61
Non Currrent Assets Other	0.39	0.25	0.31	0.44	0.44	0.27	0.39	0.25	0.37		0.3	0.3	-0.08	-0.01	0.5	0.19	0.21	0.19	0.39	0.27	0.35	0.14	-0.44	-0.01	0.0	0.41
Cash And Short Term Investments	0.77	0.65	0.81	0.6	0.25	0.4	0.64	0.92	0.61	0.3		0.75	0.67	0.43	0.56	0.62	-0.22	0.66	0.63	0.36	0.86	0.64	0.09	-0.23	-0.23	0.44
Net Receivables	0.97	0.93	0.86	0.9	0.67	0.24	0.92	0.47	0.92	0.3	0.75		0.83	0.49	0.8	0.58	-0.22	0.92	0.89	0.85	0.88	0.94	-0.01	-0.24	-0.24	0.62
Good Will	0.81	0.83	0.71	0.73	0.49	0.21	0.77	0.48	0.79	-0.08	0.67	0.83		0.46	0.63	0.48	-0.36	0.76	0.76	0.69	0.71	0.93	0.25	-0.26	-0.26	0.4
Common Stock Shares Outstanding	0.5	0.53	0.57	0.4	0.12	-0.04	0.42	0.39	0.39	-0.01	0.43	0.49	0.46		0.27	0.8	0.08	0.69	0.39	0.36	0.58	0.42	-0.18	-0.78	-0.78	0.37
Non Current Liabilities Total	0.86	0.88	0.56	0.96	0.93	0.02	0.96	0.36	0.95	0.5	0.56	0.8	0.63	0.27		0.51	-0.28	0.76	0.97	0.85	0.61	0.83	-0.04	-0.2	-0.2	0.5
Inventory	0.59	0.65	0.56	0.55	0.32	-0.22	0.57	0.57	0.52	0.19	0.62	0.58	0.48	0.8	0.51		-0.19	0.78	0.59	0.41	0.63	0.51	0.01	-0.6	-0.6	0.18
Other Current Assets	-0.12	-0.3	0.04	-0.23	-0.26	0.52	-0.3	-0.11	-0.24	0.21	-0.22	-0.22	-0.36	0.08	-0.28	-0.19		-0.29	-0.3	-0.16	0.0	-0.31	-0.39	-0.22	-0.22	0.44
Other Stockholder Equity	0.88	0.93	0.73	0.85	0.64	-0.08	0.89	0.41	0.85	0.19	0.66	0.92	0.76	0.69	0.76	0.78	-0.29		0.86	0.82	0.77	0.87	0.06	-0.37	-0.37	0.47
Total Liab	0.92	0.96	0.65	0.99	0.88	0.04	0.99	0.41	0.98	0.39	0.63	0.89	0.76	0.39	0.97	0.59	-0.3	0.86		0.9	0.7	0.92	0.04	-0.25	-0.25	0.52
Property Plant And Equipment Gross	0.85	0.91	0.57	0.93	0.87	0.03	0.91	0.08	0.94	0.27	0.36	0.85	0.69	0.36	0.85	0.41	-0.16	0.82	0.9		0.57	0.89	0.01	-0.2	-0.19	0.6
Total Current Assets	0.89	0.74	0.99	0.7	0.37	0.49	0.73	0.71	0.72	0.35	0.86	0.88	0.71	0.58	0.61	0.63	0.0	0.77	0.7	0.57		0.75	-0.1	-0.32	-0.32	0.68
Intangible Assets	0.93	0.94	0.74	0.9	0.74	0.16	0.93	0.38	0.94	0.14	0.64	0.94	0.93	0.42	0.83	0.51	-0.31	0.87	0.92	0.89	0.75		0.15	-0.22	-0.22	0.54
Other Current Liab	-0.04	0.09	-0.1	-0.06	-0.07	-0.23	0.0	0.14	0.03	-0.44	0.09	-0.01	0.25	-0.18	-0.04	0.01	-0.39	0.06	0.04	0.01	-0.1	0.15		0.5	0.5	-0.21
Common Stock Total Equity	-0.29	-0.31	-0.29	-0.28	-0.1	0.0	-0.24	-0.26	-0.23	-0.01	-0.23	-0.24	-0.26	-0.78	-0.2	-0.6	-0.22	-0.37	-0.25	-0.2	-0.32	-0.22	0.5		1.0	-0.18
Common Stock	-0.29	-0.31	-0.29	-0.28	-0.1	0.0	-0.23	-0.26	-0.23	0.0	-0.23	-0.24	-0.26	-0.78	-0.2	-0.6	-0.22	-0.37	-0.25	-0.19	-0.32	-0.22	0.5	1.0		-0.17
Other Assets	0.71	0.5	0.72	0.59	0.41	0.67	0.57	0.31	0.61	0.41	0.44	0.62	0.4	0.37	0.5	0.18	0.44	0.47	0.52	0.6	0.68	0.54	-0.21	-0.18	-0.17

Click cells to compare fundamentals

ProPhase Labs Account Relationship Matchups

ProPhase Labs fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	12.3M	31.4M	89.3M	87.6M	91.9M	96.5M
Total Current Liabilities	933K	6.3M	15.5M	16.1M	20.9M	21.9M
Total Stockholder Equity	11.2M	10.6M	58.6M	63.6M	49.4M	25.1M
Property Plant And Equipment Net	2.3M	8.3M	10.3M	11.3M	17.5M	18.3M
Net Debt	(434K)	7.9M	6.5M	(2.1M)	19.2M	20.2M
Retained Earnings	(1.5M)	(3.6M)	2.6M	11.8M	(5.0M)	(4.8M)
Accounts Payable	432K	3.8M	7.0M	5.9M	9.4M	9.9M
Cash	434K	6.8M	8.4M	9.1M	2.1M	2.0M
Non Current Assets Total	2.3M	15.5M	28.0M	26.8M	44.3M	46.6M
Non Currrent Assets Other	(2.3M)	5.1M	1.1M	1.3M	2.0M	2.1M
Cash And Short Term Investments	1.4M	8.5M	17.3M	17.4M	4.7M	8.0M
Net Receivables	6.8M	3.2M	37.7M	37.1M	36.3M	38.1M
Common Stock Shares Outstanding	11.6M	11.6M	18.4M	18.7M	17.2M	15.2M
Liabilities And Stockholders Equity	12.3M	31.4M	89.3M	87.6M	91.9M	96.5M
Non Current Liabilities Total	110K	14.6M	15.1M	7.9M	21.7M	22.8M
Inventory	1.5M	3.0M	4.6M	4.0M	3.8M	2.9M
Other Current Assets	304K	2.5M	1.7M	2.4M	2.7M	4.2M
Other Stockholder Equity	12.7M	14.2M	56.1M	51.1M	54.7M	57.4M
Total Liab	1.0M	20.8M	30.7M	24.0M	42.5M	44.7M
Property Plant And Equipment Gross	2.3M	3.6K	10.3M	11.3M	29.0M	30.5M
Total Current Assets	9.9M	15.9M	61.3M	60.8M	47.6M	27.5M
Other Current Liab	397K	1.7M	3.8M	2.9M	3.0M	3.3M
Accumulated Other Comprehensive Income	(2K)	(11K)	(175K)	757K	(300K)	(315K)
Property Plant Equipment	2.5M	2.3M	8.3M	10.3M	11.9M	12.5M
Current Deferred Revenue	104K	169K	2.0M	2.5M	2.4M	1.8M
Net Tangible Assets	16.5M	11.2M	8.4M	42.1M	48.4M	50.8M
Retained Earnings Total Equity	20.9M	4.5M	(1.5M)	(3.6M)	(4.2M)	(4.4M)
Short Term Investments	926K	1.6M	8.9M	8.3M	3.1M	4.1M
Capital Surpluse	58.0M	59.5M	60.2M	61.7M	70.9M	58.8M

Currently Active Assets on Macroaxis

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America
S	SentinelOne
WD	Walker Dunlop

When determining whether ProPhase Labs offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ProPhase Labs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Prophase Labs Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Prophase Labs Stock:

How To Invest In ProPhase

Details

Is ProPhase Stock a good investment?

Details

What is ProPhase Labs' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProPhase Labs. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.

You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProPhase Labs. If investors know ProPhase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.95)

Earnings Share

(1.53)

Revenue Per Share

0.996

Quarterly Revenue Growth

(0.81)

Return On Assets

(0.23)

The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ProPhase Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProPhase Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProPhase Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ProPhase Total Liab vs Inventory Analysis

Total Liab vs Inventory

Total Liab vs Inventory Correlation Analysis

Correlation Coefficient

Total Liab

Inventory

ProPhase Labs fundamental ratios Correlations

ProPhase Labs Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ProPhase Labs fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Total Equity
Total Current Assets	+ 0.99	Total Stockholder Equity
Accounts Payable	+ 0.99	Property Plant And Equipment Net
Non Current Assets Total	+ 0.99	Property Plant And Equipment Net
Total Liab	+ 0.99	Property Plant And Equipment Net
Non Current Assets Total	+ 0.99	Accounts Payable

Common Stock	- 0.78	Common Stock Shares Outstanding
Common Stock Total Equity	- 0.78	Common Stock Shares Outstanding
Common Stock	- 0.6	Inventory
Common Stock Total Equity	- 0.6	Inventory
Other Current Liab	- 0.44	Non Currrent Assets Other
Other Current Liab	- 0.39	Other Current Assets